SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-057538
Filing Date
2022-09-21
Accepted
2022-09-21 06:04:03
Documents
4
Period of Report
2022-09-21

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea166108-6k_biondvax.htm 6-K 11387
2 PRESS RELEASE, DATED SEPTEMBER 20, 2022 ea166108ex99-1_biondvax.htm EX-99.1 14556
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10905
4 GRAPHIC ex99-1_002.jpg GRAPHIC 17391
  Complete submission text file 0001213900-22-057538.txt   66274
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 221254974
SIC: 2836 Biological Products, (No Diagnostic Substances)